Eli Lilly Forecasts 27% Growth at 46x P/E Versus Novo's 13x
Eli Lilly forecasts 27% revenue growth in fiscal 2026 driven by its GLP-1 treatments Mounjaro and Zepbound, trading at a 46x forward P/E multiple. Novo Nordisk anticipates a 5%-13% sales decline due to compounded drug competition while trading at a 13x P/E, prompting some investors to favor its lower valuation.
1. Growth Projection for Eli Lilly
Eli Lilly expects 27% revenue growth in fiscal 2026, led by escalating demand for its GLP-1 therapies Mounjaro and newly approved Zepbound, highlighting strong momentum in its obesity and diabetes franchise.
2. Premium Valuation vs. Novo Nordisk
Lilly shares trade at a 46x forward P/E, over three times Novo Nordisk’s 13x multiple, raising concerns over whether the premium valuation can be justified by future earnings.
3. Novo Nordisk’s Competitive Position
Novo Nordisk projects a 5%-13% sales decline as compounded GLP-1 alternatives pressure its market share, yet its lower valuation and upcoming GLP-1 weight loss pill rollout offer a potential rebound pathway.